The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia
about
Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid LeukemiaPersonalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA AnalysisA study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder.Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs.OCT1 and imatinib transport in CML: is it clinically relevant?Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia.Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia.Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers.Polycomb genes are associated with response to imatinib in chronic myeloid leukemia.Toward Precision Medicine: How Far Is the Goal?The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition.
P2860
Q26781539-9122B832-D6A6-4663-8CA5-29C937E2777DQ26800005-E8E1F983-3387-4352-B48E-E6B59CA80B0BQ33427392-CBF957FC-4FA8-4F33-800F-480484CE950CQ36229161-85F57EEF-F0CB-479D-868E-DBA6C1673962Q36808178-BBA26D12-1A45-48F3-927F-313CD3B97E66Q37685527-38B54658-4C62-402D-9691-4CD592E2E12EQ38513661-E5F2CB79-457A-49D8-9467-4314F995730CQ38540022-E645C24D-D29A-4F19-A1AF-71F8C23B786DQ38622785-B79D225E-D104-456A-912A-299FF3B05236Q38826494-3019B0DE-C068-417B-BF2A-0CA41B63A539Q38888369-18AD6D3B-8583-4EF3-9EA0-6E1BC4DF50D0Q38910072-A7075C73-E479-4A5A-A7CA-78F36B431A98Q39429836-703658B2-6129-43B5-8C13-70A25F542467Q40721053-B1350055-554C-42E0-9CE9-F7F7C602D96AQ41346071-DFFCD2D8-7FC0-4DD1-AC58-79D76C50C1CCQ42672408-0AFB15E6-C9B8-4819-8FDF-C7BE18A2CB1BQ45790127-EB80FE47-285B-48D3-AC32-5CE412BD036FQ55514622-B9DFBCAB-224E-42C1-A96A-CA1FB70EAD1C
P2860
The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia
description
im März 2014 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 04 March 2014
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2014
@uk
name
The c.480C>G polymorphism of h ...... ed by chronic myeloid leukemia
@en
The c.480C>G polymorphism of h ...... ed by chronic myeloid leukemia
@nl
type
label
The c.480C>G polymorphism of h ...... ed by chronic myeloid leukemia
@en
The c.480C>G polymorphism of h ...... ed by chronic myeloid leukemia
@nl
prefLabel
The c.480C>G polymorphism of h ...... ed by chronic myeloid leukemia
@en
The c.480C>G polymorphism of h ...... ed by chronic myeloid leukemia
@nl
P2093
P2860
P50
P356
P1476
The c.480C>G polymorphism of h ...... ed by chronic myeloid leukemia
@en
P2093
E Ciabatti
F Guerrini
G Cervetti
G Fontanelli
M Capecchi
P2860
P2888
P304
P356
10.1038/TPJ.2014.7
P407
P577
2014-03-04T00:00:00Z